Article
A Genome-Wide Association Study Predicts the Onset of Dysgeusia Due to Anti-cancer Drug Treatment.
Biological & pharmaceutical bulletin - 1 Jan 2022
Takei Minori, Okada Naoto, Nakamura Shingen, Kagawa Kumiko, Fujii Shiro, Miki Hirokazu, Ishizawa Keisuke, Abe Masahiro, Sato Youichi
Abstract excerpt
Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient's QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.